RT Journal Article
T1 Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
A1 Custodio, A
A1 Jimenez-Fonseca, P
A1 Carmona-Bayonas, A
A1 Gomez, M J
A1 Del Olmo-García, M I
A1 Lorenzo, I
A1 Díaz, J Á
A1 Canal, N
A1 De la Cruz, G
A1 Villabona, C
K1 Carcinoid syndrome
K1 Costs
K1 Neuroendocrine tumour
K1 Resources
K1 Somatostatin analogues
AB To report healthcare resource use and associated costs in controlled versus uncontrolled carcinoid syndrome (CS) in patients with neuroendocrine tumours. A cross-sectional, non-interventional multicentre study was conducted with retrospective data analysis. Resource use was compared between two patient groups: those with controlled CS (> 12 months with no uncontrolled CS episodes) and uncontrolled CS ( 12 months with no uncontrolled CS episodes) and uncontrolled CS ( Twenty-six university hospitals in Spain participated, between July 2017 and April 2018. 137 patients were enrolled; 104 were analysed (2 groups of 52). Patients with uncontrolled CS had 10 times more emergency department (ED) visits (mean 1.0 vs 0.10 visits; P = 0.0167), were more likely to have a hospital admission (40.4% vs 19.2%; P = 0.0116) and had longer hospital stays (mean 7.87 vs 2.10 days; P = 0.0178) than those with controlled CS. This corresponded to higher annual hospitalisation costs (mean €5511.59 vs €1457.22; P = 0.028) and ED costs (€161.25 vs €14.85; P = 0.0236). The mean annual total healthcare costs were 60.0% higher in patients with uncontrolled than controlled CS (P = NS). This study quantifies higher health resource use, and higher hospitalisation and ED costs in patients with uncontrolled CS. Better control of CS may result 3in lower medical costs.
YR 2021
FD 2021-06-09
LK http://hdl.handle.net/10668/17983
UL http://hdl.handle.net/10668/17983
LA en
DS RISalud
RD Apr 7, 2025